Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey.

Influenza Influenza vaccination programs Pandemic preparedness Policies Public health practice Seasonal influenza vaccines Vaccination

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
08 06 2021
Historique:
received: 07 01 2021
revised: 02 04 2021
accepted: 21 04 2021
pubmed: 17 5 2021
medline: 9 7 2021
entrez: 16 5 2021
Statut: ppublish

Résumé

Despite considerable global burden of influenza, few low- and middle-income countries (LMICs) have national influenza vaccination programs. This report provides a systematic assessment of barriers to and activities that support initiating or expanding influenza vaccination programs from the perspective of in-country public health officials. Public health officials in LMICs were sent a web-based survey to provide information on barriers and activities to initiating, expanding, or maintaining national influenza vaccination programs. The survey primarily included Likert-scale questions asking respondents to rank barriers and activities in five categories. Of 109 eligible countries, 62% participated. Barriers to influenza vaccination programs included lack of data on cost-effectiveness of influenza vaccination programs (87%) and on influenza disease burden (84%), competing health priorities (80%), lack of public perceived risk from influenza (79%), need for better risk communication tools (77%), lack of financial support for influenza vaccine programs (75%), a requirement to use only WHO-prequalified vaccines (62%), and young children require two vaccine doses (60%). Activities for advancing influenza vaccination programs included educating healthcare workers (97%) and decision-makers (91%) on the benefits of influenza vaccination, better estimates of influenza disease burden (91%) and cost of influenza vaccination programs (89%), simplifying vaccine introduction by focusing on selected high-risk groups (82%), developing tools to prioritize target populations (80%), improving availability of influenza diagnostic testing (79%), and developing collaborations with neighboring countries for vaccine procurement (74%) and regulatory approval (73%). Responses varied by country region and income status. Local governments and key international stakeholders can use the results of this survey to improve influenza vaccination programs in LMICs, which is a critical component of global pandemic preparedness for influenza and other pathogens such as coronaviruses. Additionally, strategies to improve global influenza vaccination coverage should be tailored to country income level and geographic location.

Identifiants

pubmed: 33992439
pii: S0264-410X(21)00502-8
doi: 10.1016/j.vaccine.2021.04.043
pii:
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3419-3427

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors declare that they have no competing financial interests that could have influenced the work reported in this paper. P Lambach works for the World Health Organization (WHO). The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy or views of the WHO. J Bresee works for the CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US CDC.

Auteurs

Alison M Kraigsley (AM)

Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, MN, USA. Electronic address: AMK@umn.edu.

Kristine A Moore (KA)

Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, MN, USA.

Amanda Bolster (A)

The Task Force for Global Health, Atlanta, GA, USA.

Maya Peters (M)

Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, MN, USA.

Dominique Richardson (D)

The Task Force for Global Health, Atlanta, GA, USA.

Meredith Arpey (M)

Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, MN, USA.

Michelle Sonnenberger (M)

Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.

Margaret McCarron (M)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Philipp Lambach (P)

World Health Organization, Geneva, Switzerland.

Helena C Maltezou (HC)

Directorate of Research, Studies and Documentation, National Public Health Organization, Athens, Greece.

Joseph S Bresee (JS)

The Task Force for Global Health, Atlanta, GA, USA; Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH